CAMBRIDGE, UK & BILLERICA, Mass.--(BUSINESS WIRE)--Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ...
Drug developers are consistently aiming to enhance clinical relevance in drug discovery. CRISPR has emerged as a versatile tool to accelerate the entire drug discovery process, with arrayed CRISPR ...
In this file photo taken on January 27, 2021, Palestinian doctors and technicians work at the IVF laboratory at the Razan Center fertility clinic in Nablus, in the ...
(Nanowerk Spotlight) For decades, microfluidics has held promise as a revolutionary technology, yet widespread adoption outside research labs has remained elusive. Microfluidic devices enable precise ...
Digital microfluidics encompasses the precise manipulation of discrete droplets on an array of electrodes, typically by modulating interfacial tension through applied electric fields. Electrowetting ...
Conventional manufacturing methods such as soft lithography and hot embossing processes can be used to bioengineer microfluidic chips, albeit with limitations, including difficulty in preparing ...
CAMBRIDGE, UK & BILLERICA, Mass.--(BUSINESS WIRE)--Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ...
This morning, E Ink announced that their digital microfluidics unit has been acquired by Nuclera, a UK-based biotech company. The acquisition combines the tech of the two companies to create a desktop ...
UK-based biotech firm Nuclera has announced it has acquired Taiwan-based E Ink Holdings (EIH)'s digital microfluidics unit to form its US subsidiary. Combining the technologies of the two companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results